Sharma Devanshi, Gajjar Devanshi, Seshadri Sriram
Institute of Science, Nirma University, 382481 Ahmedabad, Gujarat, India.
Microbiome Res Rep. 2023 Oct 31;3(1):3. doi: 10.20517/mrr.2023.51. eCollection 2024.
Gut microbiota research has gained a tremendous amount of attention from the scientific community because of its contribution to gut homeostasis, human health, and various pathophysiological conditions. The early colonizer of the human gut, i.e., bifidobacteria, has emerged as an efficient probiotic in various diseased conditions, including cancer. This review explores the pros and cons of in various malignancies and various therapeutic strategies. We have illustrated the controversial role of bifidobacteria participating in various malignancies as well as described the current knowledge regarding its use in anticancer therapies. Ultimately, this article also addresses the need for further extensive research in elucidating the mechanism of how bifidobacteria is involved and is indirectly affecting the tumor microenvironment. Exhaustive and large-scale research is also required to solve the controversial questions regarding the involvement of bifidobacteria in cancer research.
由于肠道微生物群对肠道稳态、人类健康和各种病理生理状况的贡献,它的研究已引起科学界的极大关注。人类肠道的早期定植菌,即双歧杆菌,已成为包括癌症在内的各种疾病状态下的一种有效益生菌。本综述探讨了双歧杆菌在各种恶性肿瘤中的利弊以及各种治疗策略。我们阐述了双歧杆菌在各种恶性肿瘤中所起的争议性作用,并描述了目前关于其在抗癌治疗中应用的知识。最终,本文还强调了进一步广泛研究以阐明双歧杆菌如何参与并间接影响肿瘤微环境机制的必要性。为解决关于双歧杆菌参与癌症研究的争议性问题,也需要进行详尽的大规模研究。